Analysis in progress
Initialising…
0%
complete
This report is still being assembled — sections appear as each stage finishes. It isn't final yet.
POLE
Final classification
VUS
POLE c.4501G>A · p.Gly1501Arg
POLE

PM2 (Supporting): ultra-rare population frequency — gnomAD v4.1 total AF 9.3e-06 with 0 homozygotes, far below the 0.1% cap.

Gene
POLE
Transcript
NM_006231.4
HGVS · transcript:coding
NM_006231.4:c.4501G>A
Consequence
N/A
GRCh38
chr12:132643274 C>T
GRCh37
chr12:133219860 C>T
Basis VUS: the only met criterion is PM2_Supporting (gnomAD v4.1 total AF 9.3e-06, 0 homozygotes), which alone satisfies no ACMG/AMP 2015 combination rule.
VUS: the only met criterion is PM2_Supporting (gnomAD v4.1 total AF 9.3e-06, 0 homozygotes), which alone satisfies no ACMG/AMP 2015 combination rule.
Classification rationale
PM2 VUS
POLE c.4501G>A

PM2 (Supporting): ultra-rare population frequency — gnomAD v4.1 total AF 9.3e-06 with 0 homozygotes, far below the 0.1% cap. Final classification: Uncertain Significance (VUS) — the single PM2_Supporting criterion satisfies no pathogenic or benign combination rule under ACMG/AMP 2015.

PM2 VUS
Gene diagram · NM_006231.4 · variants mapped to exon structure
POLE NM_006231.4
Fetching transcript structure from UCSC…
Applied criteria · 1 applied · 23 assessed
Applied · 1
Strength Supporting Moderate Strong Very strong
PM2 supporting Pathogenic
Met (Supporting): gnomAD v4.1 total allele frequency 9.3e-06, far below the 0.1% PM2 cap, with zero homozygotes.
gnomAD v4.1 (gnomad_v4): total AF 9.295e-06 (0.00093%), 15/1,613,766 alleles, 0 homozygotes; AFR subpopulation AF 5.339e-05 (0.00534%); joint grpmax FAF 1.746e-05 - all far below 0.1% PM2 capgnomAD v2.1 (gnomad_v2): total AF 8.045e-06 (0.00080%), 2/248,590 alleles, 0 homozygotesgnomAD-Canada v1.0 (gnomad_canada): variant absent
Assessed · not applied
Pathogenic
PS1 Not met: no pathogenic record of p.Gly1501Arg via a different nucleotide change exists; ClinVar classifies this variant as Uncertain significance.
PS2 Not assessed: no de novo occurrence of this variant in a tested proband is documented in any source.
PS3 Not assessed: no variant-specific functional study of p.Gly1501Arg exists; OncoKB reports no functional evidence.
PS4 Not met: the variant is absent from the Leon-Castillo recurrent-variant table and COSMIC, failing the somatic-recurrence rule.
PM1 Not met: residue 1501 lies outside the exonuclease proofreading domain (residues 286-459) containing all established hotspots.
PM3 Not assessed: no proband genotyping or phase data exist to test for a variant in trans with a pathogenic allele.
PM5 Not assessed: no pathogenic comparator at residue 1501 was found, though its absence is not comprehensively confirmed.
PM6 Not assessed: no de novo occurrence is documented with or without parentage confirmation.
PP1 Not assessed: no segregation or family-testing data document any informative meiosis.
PP2 Not assessed: no gene-level missense constraint data (e.g., gnomAD Z-score) are available to evaluate this rule.
PP3 Not met: REVEL 0.492 falls below the supporting threshold of 0.644, and SpliceAI max delta 0.01 shows no splice impact.
PP4 Not assessed: no phenotype or family-history data for any carrier are available.
PP5 Not met: ClinVar classifies this variant as Uncertain significance with no expert-panel submission.
Benign
BA1 Not met: highest observed allele frequency 0.00534% is roughly 300-fold below the 5% BA1 threshold.
BS1 Not met: gnomAD v4.1 frequency 0.00093% is about 1,000-fold below the 1% threshold and 60-100x below the 0.3% convention.
BS2 Not met: zero homozygotes in gnomAD v2.1 and v4.1, and reference cohorts are not cancer-screened.
BS3 Not assessed: no well-established functional study shows a lack of damaging effect for p.Gly1501Arg.
BS4 Not assessed: no affected relative has been tested and shown not to carry the variant.
BP1 Not met: missense in the POLE exonuclease domain is an established disease mechanism, not primarily truncating variants.
BP2 Not assessed: no second POLE variant or phase data exist to establish cis/trans configuration.
BP4 Not met: REVEL 0.492 is far above the benign supporting threshold of 0.016.
BP5 Not assessed: no case-level information documents an alternate molecular basis in a carrier.
BP6 Not met: ClinVar classifies this variant as Uncertain significance with no expert-panel benign classification.
N/A · 4 PVS1 · PM4 · BP3 · BP7
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 9.29503e-06; MAF= 0.00093%, 15/1613766 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 5.33874e-05; MAF= 0.00534%, 4/74924 alleles, homozygotes = 0); grpmax FAF= 1.746e-05.
v2.1
This variant is present in gnomAD v2.1 (AF= 8.04538e-06; MAF= 0.00080%, 2/248590 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 0.00016415; MAF= 0.01641%, 1/6092 alleles, homozygotes = 0).
🇨🇦 CA
Absent from gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
0.00093% · 15 / 1,613,766
0 hom · FAF 0.0017%
African/African American
4 / 74,924
0.0053%
Remaining individuals
1 / 62,482
0.0016%
European (Finnish)
1 / 63,716
0.0016%
South Asian
1 / 91,094
0.0011%
European (non-Finnish)
8 / 1,180,044
0.00068%
+ 5 not observed (Admixed American, Amish, East Asian, Middle Eastern, Ashkenazi Jewish)
gnomAD v2.1
0.0008% · 2 / 248,590
0 hom
Remaining individuals
1 / 6,092
0.016%
South Asian
1 / 30,584
0.0033%
+ 6 not observed (African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish))
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant has been reported in ClinVar as Uncertain significance (2 clinical laboratories). (ClinVarID = 473668)
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.492. BayesDel score = 0.0694247.
Functional / OncoKB screenshot
Functional Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high m
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant hotspot.
Sources & reference links
8Sources
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots
Triaged references · 1 PMID not cited in assessment
25394175 ↗ A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. CLINVAR